1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Amphastar Receives FDA Approval For Regadenoson Following Solid Q1

Multiple Pipeline Launches Expected For H2

 
• By Chloe Kent

Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.

Ariel view of gas pipeline
Amphastar expects to launch at least two new generics this year • Source: Shutterstock

Amphastar Pharmaceuticals, Inc. has received approval from the US Food and Drug Administration for its generic regadenoson injection 0.08mg/ml 5ml single dose pre-filled syringe. The agency has approved the firm’s abbreviated new drug application for the drug, determining that it is bioequivalent and therapeutically equivalent to Astellas Pharma’s branded regadenoson, Lexiscan.

Company CEO and president Jack Zhang confirmed that both the finished product and the active pharmaceutical ingredient will be produced...

Welcome to Generics Bulletin

Create an account to read this article

Already a subscriber?

More from Earnings

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs

 
• By Urtė Fultinavičiūtė

As Amneal reports another solid quarterly performance, with refinanced debt and adjusted financial guidance for the year, will Trump’s “chaotic” tariffs shake it all up?

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

More from Business

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By Dean Rudge

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.

‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs

 
• By Urtė Fultinavičiūtė

As Amneal reports another solid quarterly performance, with refinanced debt and adjusted financial guidance for the year, will Trump’s “chaotic” tariffs shake it all up?

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.